PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on...
PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on...
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Predictive...
Investment creates the world’s first Strategic Compute Reserve Strategy complements Predictive Oncology’s AI/ML-driven drug discovery and development activities PITTSBURGH, Oct. 08, 2025...
Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its...
PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will effect a 1-for-15 reverse...
PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying...
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive...
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the...